Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export Justin C. BaderAlbiruni R. Abdul RazakHongmei Xu Review Article 29 April 2021 Pages: 957 - 969
Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability Shirley M. TsunodaChristopher GonzalesJoseph D. Ma Review Article Open access 07 May 2021 Pages: 971 - 984
Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review Erin ChungJonathan SenWinnie Seto Systematic Review 18 May 2021 Pages: 985 - 1001
Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women Robert A. FeldmanYi-Lin ChiuJuki Ng Original Research Article Open access 22 March 2021 Pages: 1003 - 1013
Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials Birgitte Bentz DamholtSarah Louise DombernowskyMichael Højby Rasmussen Original Research Article Open access 23 March 2021 Pages: 1015 - 1027
Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease Yan XinFengyan XuSrini Ramanathan Original Research Article Open access 26 March 2021 Pages: 1029 - 1040
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil Ashit TrivediRajneet K. OberoiEdward Lee Original Research Article Open access 26 March 2021 Pages: 1041 - 1048
Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide Shweta UrvaTonya QuinlanCorina Loghin Original Research Article Open access 29 March 2021 Pages: 1049 - 1059
Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure Takeru NabetaKeisuke KidaTakayuki Inomata Original Research Article Open access 30 March 2021 Pages: 1061 - 1071
Comment on: “Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation” Satish SuhasVijay KumarBangalore N. Gangadhar Letter to the Editor 26 April 2021 Pages: 1073 - 1075
Authors’ Reply to Suhas et al.: Comment on: “Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation” Georgios SchoretsanitisMaxim KuzinEkkehard Haen Letter to the Editor 26 April 2021 Pages: 1077 - 1079